Trastuzumab-containing regimens for metastatic breast cancer.


BACKGROUND Patients with breast cancer are classified as having cells that over-express the human epidermal growth factor receptor 2 (known as HER2-positive) or not (HER2-negative). Typically, patients with HER2-positive disease have a worse prognosis. Trastuzumab is a selective treatment that targets the HER2 pathway. The available evidence supporting… (More)
DOI: 10.1002/14651858.CD006242.pub2

4 Figures and Tables


  • Blog articles referencing this paper

  • Presentations referencing similar topics